Literature DB >> 7721389

Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist.

J S Li1, E L Schiffrin.   

Abstract

We previously showed that endothelin-1 expression was increased in vascular endothelium of deoxycorticosterone acetate-salt hypertensive rats, whereas in spontaneously hypertensive rats (SHR) it is similar to or less than that in normotensive rats. Treatment with the combined endothelin type A/endothelin type B receptor antagonist bosentan moderately reduced blood pressure rise and nearly completely blunted the development of vascular hypertrophy, particularly in small arteries, in the deoxycorticosterone acetate-salt hypertensive model, suggesting a paracrine role for vascular endothelin-1 in the induction of blood vessel hypertrophy in some forms of experimental hypertension. In the present study we examined the effect of chronic oral treatment for 4 weeks of 12-week-old SHR and Wistar-Kyoto rats (WKY) with 100 mg/kg per day bosentan. Blood pressure rose to hypertensive levels similarly in bosentan-treated and untreated SHR; systolic pressure of WKY was also unaffected. The wet weights of the heart, of aortic segments, and of the mesenteric arterial bed were similar in treated and untreated SHR. When coronary, renal arcuate, mesenteric, and femoral small arteries were evaluated on a wire myograph, the media width and media-to-lumen ratio were greater and the lumen diameter was smaller in vessels from SHR relative to those from WKY, except in small arteries from the renal cortex, in which the lumen was not significantly different in both strains. The media cross-sectional area of small arteries fom the four vascular beds was similar in both strains. Identical morphometric parameters were found in the four vascular beds in bosentan-treated and untreated rats of eh strain.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721389     DOI: 10.1161/01.hyp.25.4.495

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

Review 1.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 3.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

4.  An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor heterozygous mice but not in null mice.

Authors:  Nan Zhang; Larry N Agbor; Jason A Scott; Tyler Zalobowski; Khalid M Elased; Alicia Trujillo; Melissa Skelton Duke; Valerie Wolf; Mary T Walsh; Jerry L Born; Linda A Felton; Jian Wang; Wei Wang; Nancy L Kanagy; Mary K Walker
Journal:  Biochem Pharmacol       Date:  2010-03-30       Impact factor: 5.858

Review 5.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

6.  Effects of several endothelin receptor antagonists on gastrointestinal transit of guinea pigs.

Authors:  K Kuwahara; Y Kitsukawa; Y Suzuki; Y Saito
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

7.  An experimental model for hypertensive crises emergencies: Long-term high-fat diet followed by acute vasoconstriction stress on spontaneously hypertensive rats.

Authors:  Hong Liu; Wei-Wei Su; Chao-Feng Long; Wei-Jian Zhang; Pei-Bo Li; Zhong Wu; Yin-Yin Liao; Xuan Zeng; Tao-Bin Chen; Yu-Ying Zheng; Zeng-Hao Yan; Cong Bi; Hong-Liang Yao
Journal:  Exp Biol Med (Maywood)       Date:  2018-02-14

Review 8.  Endothelin and its antagonists in hypertension: can we foresee the future?

Authors:  P Moreau; T J Rabelink
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

9.  Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.

Authors:  E L Schiffrin; P Sventek; J S Li; A Turgeon; T Reudelhuber
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

10.  Tension Measurement in Isolated Rat and Mouse Pulmonary Artery.

Authors:  Eun A Ko; Michael Y Song; Reshma Donthamsetty; Ayako Makino; Jason X-J Yuan
Journal:  Drug Discov Today Dis Models       Date:  2011-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.